Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Reducing expression of the fetal hemoglobin (HbF) repressor BCL11A leads to a simultaneous increase in γ-globin expression and reduction in β-globin expression. Thus, there is interest in targeting BCL11A as a treatment for β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia. Here, we found that using optimized shRNAs embedded within an miRNA (shRNAmiR) architecture to achieve ubiquitous knockdown of BCL11A profoundly impaired long-term engraftment of both human and mouse hematopoietic stem cells (HSCs) despite a reduction in nonspecific cellular toxicities. BCL11A knockdown was associated with a substantial increase in S/G2-phase human HSCs after engraftment into immunodeficient (NSG) mice, a phenotype that is associated with HSC exhaustion. Lineage-specific, shRNAmiR-mediated suppression of BCL11A in erythroid cells led to stable long-term engraftment of gene-modified cells. Transduced primary normal or SCD human HSCs expressing the lineage-specific BCL11A shRNAmiR gave rise to erythroid cells with up to 90% reduction of BCL11A protein. These erythrocytes demonstrated 60%-70% γ-chain expression (vs. < 10% for negative control) and a corresponding increase in HbF. Transplantation of gene-modified murine HSCs from Berkeley sickle cell mice led to a substantial improvement of sickle-associated hemolytic anemia and reticulocytosis, key pathophysiological biomarkers of SCD. These data form the basis for a clinical trial application for treating sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an erythroid-specific knockdown of BCL11A delivered by a lentiviral-encoded, microRNA-adapted short hairpin RNA molecule has been shown to reactivate the γ-globin gene and is in early clinical development.[17][18][19]”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Self-citationUda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V. G., Chen, W., Usala, G., Busonero, F., Maschio, A., Albai, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711566105 · Cited by 672
Self-citationAn Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Self-citationCorrection of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
The β-globin nuclear compartment in development and erythroid differentiation
Palstra, R.-J., Tolhuis, B., Splinter, E., Nijmeijer, R., Grosveld, F., & de Laat, W. (2003) · Nature Genetics · doi:10.1038/ng1244 · Cited by 559
Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Developmental and species-divergent globin switching are driven by BCL11A
Sankaran, V. G., Xu, J., Ragoczy, T., Ippolito, G. C., Walkley, C. R., Maika, S. D., Fujiwara, Y., Ito, M., Groudine, M., Bender, M. A., et al. (2009) · Nature · doi:10.1038/nature08243 · Cited by 379
Self-citationWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Xu, J., Sankaran, V. G., Ni, M., Menne, T. F., Puram, R. V., Kim, W., & Orkin, S. H. (2010) · Genes & Development · doi:10.1101/gad.1897310 · Cited by 361
Self-citation
Cited by
Items 101–170 of 170
Hemoglobinopathies and Thalassemias
Peslak, S. A., & Sayani, F. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812534-2.00009-6 · Cited by 14
Rajendiran, V., Devaraju, N., Haddad, M., Ravi, N. S., Panigrahi, L., Paul, J., Gopalakrishnan, C., Wyman, S. K., Ariudainambi, K., Mahalingam, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.023 · Cited by 13
Gene Therapy as the New Frontier for Sickle Cell Disease
Garg, H., Tatiossian, K. J., Peppel, K., Kato, G. J., & Herzog, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210527092456 · Cited by 12
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Self-citationNucleic Acid Therapy for β-Thalassemia
d’Arqom, A. (2020) · Biologics · doi:10.2147/btt.s265767 · Cited by 16
Genetic control of erythropoiesis
Tumburu, L., & Thein, S. L. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000333 · Cited by 16
Lourenço, S. P., Jarocha, D. J., Ghiaccio, V., Guerra, A., Abdulmalik, O. Y., La, P., Zezulin, A. U., Smith‐Whitley, K., Kwiatkowski, J. L., Guzikowski, V., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.276634 · Cited by 10
Innovative Therapies for Hemoglobin Disorders
Sii-Felice, K., Nègre, O., Brendel, C., Tubsuwan, A., Morel-à-l’Huissier, E., Filardo, C., & Payen, E. (2020) · BioDrugs · doi:10.1007/s40259-020-00439-6 · Cited by 10
Self-citationLarge-scale discovery of potent, compact and erythroid specific enhancers for gene therapy vectors
Psatha, N., Sova, P., Georgolopoulos, G., Paschoudi, K., Iwata, M., Bloom, J. E., Ulyanova, T., Wang, H., Kirtsou, A., Vasiloudis, N.-I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59235-x · Cited by 10
“Lentiviral vectors expressing miRNA-embedded shmiRNA targeting BCL11A were based on control vectors described above in which the GFP ORF was appended by a cassette containing BCL11A -targeting shmiRNA embedded in miR223 as described previously 20,21 .”
A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Rós, F. A., Couto, S. C. F., Milhomens, J., Ovider, I., Tozatto‐Maio, K., Jennifer, V., Ramos, R. N., Picanço‐Castro, V., Kashima, S. H., Calado, R. T., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.006 · Cited by 10
Emerging cellular and gene therapies for congenital anemias
Ludwig, L. S., Khajuria, R. K., & Sankaran, V. G. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31529 · Cited by 11
“…IIdriven shRNAs appeared to be less cytotoxic than RNA polymerase IIIbased vectors—perhaps due to lower overall expression levels of the shRNAs —implying possible preferences for using polymerase II-based strategies in clinical settings more generally [Guda et al., 2015; Brendel et al., 2016].”
BackgroundOmics Studies in Hemoglobinopathies
Katsantoni, E. Z. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00386-1 · Cited by 10
DROSHA Knockout Leads to Enhancement of Viral Titers for Vectors Encoding miRNA-Adapted shRNAs
Park, H. H., Triboulet, R., Bentler, M., Guda, S., Du, P., Xu, H., Gregory, R. I., Brendel, C., & Williams, D. A. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.002 · Cited by 10
“This can be accomplished by embedding shRNAs into flanking miRNA scaffolds, termed miRNA-adapted shRNAs (shRNAs), which mimic the structure of endogenous miRNAs as described previously by us and others.(14,15)”
BackgroundSelf-citationEpigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
“Most current gene therapy for hemoglobinopathies relies on a truncated β -globin LCR spanning a ~3 kb in size to ensure both therapeutic and erythroid-specific expression of the respective transgene [172–174].”
Gene therapy for hemoglobinopathies
Tanhehco, Y. C. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103061 · Cited by 12
Bagchi, A., Devaraju, N., Chambayil, K., Rajendiran, V., Venkatesan, V., Sayed, N., Pai, A. A., Nath, A., David, E. K., Nakamura, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13783-0 · Cited by 9
Genetic Therapies for Sickle Cell Disease
Jayavaradhan, R., & Malik, P. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.008 · Cited by 11
Hart, K. L., Liu, B., Brown, D., Campo-Fernández, B., Tam, K., Orr, K., Hollis, R. P., Brendel, C., Williams, D. A., & Kohn, D. B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101254 · Cited by 9
Self-citationLiu, B., Klatt, D., Zhou, Y., Manis, J. P., Sauvageau, G., Pellin, D., Brendel, C., & Williams, D. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013932 · Cited by 8
“The generation of LV-BCL11A (LV-LCR-mir223 BCL11A) vectors has been described previously, 13,24 and the structure is shown in supplemental Figure 1A.”
Self-citationAdvancing the care of β-thalassaemia patients with novel therapies.
Bou‐Fakhredin, R., Motta, I., & Cappellini, M. D. (2022) · Blood transfusion · doi:10.2450/2021.0265-21 · Cited by 10
Nualkaew, T., Jearawiriyapaisarn, N., Hongeng, S., Fucharoen, S., Kole, R., & Svasti, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43964-3 · Cited by 7
Gnanapragasam, M. N., Planutis, A., Glassberg, J., & Bieker, J. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-34805-5 · Cited by 7
Guerra, A., Musallam, K. M., Taher, A. T., & Rivella, S. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.002 · Cited by 7
Khosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Buch, T., & Karimipoor, M. (2019) · Data in Brief · doi:10.1016/j.dib.2019.104974 · Cited by 9
Lv, A., Chen, M., Zhang, S., Zhao, W., Li, J., Lin, S., Zheng, Y., Lin, N., Xu, L., & Huang, H. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13372 · Cited by 6
“Based on the aforementioned research, β ‑thalassemia may be treated using mirna‑based targeted therapies (57). in the present study, patients diagnosed with β ‑TM exhibited decreased levels of Bcl11a mrna expression.”
Promises and Challenges in Hematopoietic Stem Cell Gene Therapy
Kohlscheen, S., Bonig, H. B., & Modlich, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.141 · Cited by 6
Role of gene therapy in sickle cell disease
Raghuraman, A., Lawrence, R., Shetty, R., Avanthika, C., Jhaveri, S., Pichardo, B. V., & Mujakari, A. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101689 · Cited by 7
Vadolas, J., Nualkaew, T., Voon, H. P. J., Vilcassim, S., & Grigoriadis, G. (2024) · HemaSphere · doi:10.1002/hem3.78 · Cited by 5
Islam, M. R., Rauf, A., Akash, S., Sharker, M., Mahreen, M., Munira, M. A. K., Dhar, P. S., Hemeg, H. A., Iriti, M., & Imran, M. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155936 · Cited by 6
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 5
Okeke, C., Silas, U., Nnodu, O., & Clementina, O. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x17666220221104711 · Cited by 4
Rossi, M. (2023) · Science Reviews Biology · doi:10.57098/scirevs.biology.2.3.3 · Cited by 5
Esrick, E. B., Lehmann, L., Federico, A., Vincon, H., Liu, B., Daley, H., Dansereau, C., Oliveira, S. D., Everett, J. K., Kao, P., et al. (2026) · Blood · doi:10.1182/blood.2026033871 · Cited by 3
Self-citationKlatt, D., Mucci, A., Liu, B., Peschers, M., Schiroli, G., Schambach, A., Manis, J. P., Armant, M. A., Scadden, D. T., Verhoeyen, E., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.09.001 · Cited by 3
Self-citationSuwito, B. E., Adji, A. S., Widjaja, J. S., Angel, S. C. S., Hajiri, A. Z. Z. A., Salamy, N. F. W., & Choirotussanijjah, C. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.11435 · Cited by 4
Fañanas-Baquero, S., Morin, M., Fernández, S., Ojeda-Pérez, I., Dessy-Rodríguez, M., Giurgiu, M., Bueren, J. A., Moreno-Pelayo, M. Á., Segovia, J. C., & Bustamante, O. Q. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1104666 · Cited by 5
“On the other hand, the reexpression of fetal globins by gene editing is a true therapeutic alternative for the treatment of β-thalassemia and sickle cell disease (Canver et al., 2015; Brendel et al., 2016; Ye et al., 2016; Lux et al., 2019; Frangoul et al., 2021; Fu et al., 2022).”
BackgroundPooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries
Adams, F. F., Hoffmann, T., Zuber, J. A., Heckl, D., Schambach, A., & Schwarzer, A. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.182 · Cited by 3
Daniel-Moreno, A., Lamsfus‐Calle, A., Wilber, A. C., Chambers, C. B., Johnston, I., Antony, J. S., Epting, T., Handgretinger, R., & Mezger, M. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102456 · Cited by 3
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 4
Gene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
“In the third trial, the GT was aimed at increasing the synthesis of γ-globin and reducing the expression of β-globin.(54) Three months after GT was applied, a single patient showed a significant increase in foetal haemoglobin, which was 23% of the total haemoglobin.”
MethodGene Editing in Hematopoietic Stem Cells
Liao, J., & Wu, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_11 · Cited by 4
Gentherapie von Hämoglobinkrankheiten – aktuelle Konzepte und Herausforderungen
Kulozik, A. E., & Kunz, J. B. (2019) · Transfusionsmedizin · doi:10.1055/a-0825-9666 · Cited by 2
Hay, D., & Weatherall, D. J. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0005536.pub2 · Cited by 2
Artificial miRNAs are potential gene therapy tools, especially for incurable monogenic disordersPreprint
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/d5rnm · Cited by 2
CRISPR in Thalassemia: Global Research Trend Analysis
Saboor, M., Alblooshi, M. J., Alkaabi, A. A., Soozaei, F. R., & Alketbi, M. H. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2634815 · Cited by 1
“In sickle cell disease (SCD), CRISPR–Cas9 has been used to disrupt the BCL11A enhancer in hematopoietic stem cells (HSCs), reactivating HbF and reducing transfusion dependence [7,8].”
de Azevedo, J. T. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-14112019-123958 · Cited by 2
Hay, D., & Weatherall, D. J. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0002274.pub3 · Cited by 1
Hematopoietic Cell Transplant and Cellular Therapies for Sickle Cell Disease
Hanna, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_25
Pattabhi, S., Lotti, S. N., Berger, M. P., Singh, S., & Rawlings, D. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.30.450644
Gene Therapy: Hemoglobinopathies
(2015) · Sage eBooks · doi:10.4135/9781483347660.n159
Applied Stem Cell Research in Sickle Cell Disease
Kiumarsi, A., Rostami, T., & Mohammadi, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00027-5
Ramadier, S. (2020) · theses.fr (ABES) · doi:10.70675/b75724f6zb386z4f05zae5dzc8f17b350499
Sécurisation de la thérapie génique par CRISPR-Cas9 dans les pathologies du globule rouge
Boutin, J. (2021) · theses.fr (ABES) · doi:10.70675/aa1d0b59z401cz4506zacd4z39e9fd3c090b
Hodonsky, C. J., Baldassari, A., Bien, S. A., Raffield, L. M., Highland, H. M., Sitlani, C. M., Wojcik, G. L., Tao, R., Graff, M., Tang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986179
Revisiting γ-globin gene repression by TR4
Perkins, A. C. (2024) · Blood · doi:10.1182/blood.2024026481
Hodonsky, C. J., Baldassari, A., Bien, S. A., Raffield, L. M., Highland, H. M., Sitlani, C. M., Wojcik, G. L., Tao, R., Graff, M., Tang, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986170
Segura, E. (2025) · eScholarship (California Digital Library)
Enfoque terapéutico de la anemia falciforme
Soto-Manzano, A. V., Córdoba-García, S., Castaño, L. M. F., Uribe-Ramírez, M., & Sánchez, L. M. M. (2025) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1553
Therapeutic Genome Engineering for the Treatment of Sickle Cell Disease
Leonard, A. K., Sharma, A., Chao, F.-Y., & Yen, J. S. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_9 · Cited by 1
Déterminants de la réponse à l'Hydroxyurée au cours du traitement de la drépanocytose
Rakotoson, M. G. (2016) · theses.fr (ABES) · doi:10.70675/29250363zfe0bz41aaz860azcc473ae41b1f · Cited by 1
Antoniani, C. (2017) · theses.fr (ABES) · doi:10.70675/fa4f556cza36dz42efz9910zbd602b77cff5
New therapeutic strategies for the treatment of β-hemoglobinopathies
Weber, L. (2018) · theses.fr (ABES) · doi:10.70675/09314463zdfd1z46b4z9c0cz32c6c2c5ccc2
Base editing approaches for the treatment of β-hemoglobinopathies
Antoniou, P. (2021) · theses.fr (ABES) · doi:10.70675/c4dddb32zf8aez4bc3z8cf8zce9a4e808265
Development of gene therapy approaches to ß-hemoglobinopathies
Chalumeau, A. (2023) · theses.fr (ABES) · doi:10.70675/7fc1b037zbffbz4005z9109zd81aa6f38a83
Etude des régulateurs et des voies moléculaires impliqués dans les conversions d'état cellulaire
Trajkova, A. (2024) · theses.fr (ABES) · doi:10.70675/87dd8564zbfd1z4a6ezbc15z8a3402efe338
The Molecular Pathology of Non-Malignant Haematological Disease
Blann, A. D., & Dunn, R. G. (2026) · British Journal of Biomedical Science · doi:10.3389/bjbs.2026.14743 · Cited by 1
Gene Therapy and CRISPR-based Intervention in Sickle Cell Anemia
Dere, V. V., Patil, S. S., Kale, A. Y., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3515
Altayar, M. A. (2026) · Diagnostics · doi:10.3390/diagnostics16152448
“…instead promote definitive, adult-type erythropoiesis—such as bone marrow-derived starting material and optimized stromal coculture—remain the more direct approaches to jointly addressing HbF prevalence, maturation, and enucleation as linked outputs of the same developmental program [52,54,56,71].”
An Integrated Gene Therapy Strategy for γ-Globin Addition and HbF Reactivation in β-Thalassemia
Paschoudi, K., Vasiloudis, N.-I., Papadopoulos, F., Nikolaou, X., Παπαδοπούλου, Α., Sova, P., Yannaki, E., & Psatha, N. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030019
“…editing of the erythroid-specific BCL11A (a key γ -globin repressor) enhancer [33–39] and erythroid-restricted BCL11A knockdown using lentiviral shRNA or shmiR constructs [40–43] can induce HbF from the endogenous β -globin locus without requiring the introduction of an additional globin transgene.”
Influential
Metadata
- Authors
- Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., Orkin, S. H., Gregory, R. I., & Williams, D. A.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Medizinische Hochschule Hannover (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-09-06
- Volume
- 126
- Issue
- 10
- Pages
- 3868-3878
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5096824
- OpenAlex
- W2513179752
- Cited by
- 167
- References
- 45
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 17 · 2023: 15 · 2022: 15 · 2021: 26 · 2020: 26 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 3
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- bluebird bio
- Centre Hospitalier Universitaire Vaudois
- National Institutes of Health (DK093705)
- National Heart, Lung, and Blood Institute (U01HL117720)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK103359, K08DK093705)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- BCL11A, sickle cell disease, beta-thalassemia, hematopoietic engraftment, HSC exhaustion, γ-globin expression, erythroid cells, hemolytic anemia, reticulocytosis, gene therapy
- MeSH terms
- Anemia, Sickle Cell, Animals, Carrier Proteins, Cells, Cultured, Graft vs Host Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mice, Inbred C57BL, Nuclear Proteins, Phenotype, Repressor Proteins, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Cell Lineage, RNA, Small Interfering, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.